Dose-response Association of Metformin Use and Risk of Age-related Macular Degeneration Among Patients with Type 2 Diabetes Mellitus: a Population-based Study

Overview

Journal Front Pharmacol

Date 2023 Dec 11

PMID 38074151

Authors

Kuang-Hua Huang

Ya-Lan Chang

Chiachi Bonnie Lee

Shuo-Yan Gau

Tung-Han Tsai

Ning-Jen Chung

Chien-Ying Lee

Affiliations

Soon will be listed here.

Abstract

Recent studies have demonstrated that patients with type 2 diabetes mellitus (T2DM) who receive metformin have a decreased risk of developing age-related macular degeneration (AMD). However, other studies have also suggested that metformin may increase the risk of AMD development. Therefore, this study investigated the association between treatment with metformin and the risk of AMD in patients with T2DM by using Taiwan' National Health Insurance Research Database. Patients who received a diagnosis of new-onset T2DM between 2002 and 2013 were enrolled in this study. The patients were divided into patients treated and not treated with metformin to evaluate the risk of AMD after 5 years of follow-up. The logistic regression was used to estimate the risk of AMD associated with the intensity of treatment with metformin. A total of 7 517 patients (103.16 patients per 10,000 people) developed AMD in 5 years after DM diagnosis. After adjusting for the relevant variables, patients with T2DM treated with <5 defined daily dose (DDD)/month of metformin had a lower risk of AMD (odds ratios [OR]: 0.93; 95% confidence interval [CI]: 0.88 0.99). Patients treated with >25 DDD/month of metformin had a higher risk of AMD (OR: 1.39; 95% CI: 1.08-1.78). Metformin use may be associated with a risk of AMD among patients with T2DM in a dose-dependent association manner, with the greater benefit at lower DDD/month. However, higher DDD/month exhibited an increased risk of AMD.

Citing Articles

Revolutionary drug repositioning: the preventive and therapeutic potential of metformin and other antidiabetic drugs in age-related macular degeneration.

Zhou Y, Xue F Front Pharmacol. 2024; 15:1507860.

PMID: 39720591 PMC: 11666363. DOI: 10.3389/fphar.2024.1507860.

References

Hou X, Song J, Li X, Zhang L, Wang X, Chen L . Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun. 2010; 396(2):199-205. DOI: 10.1016/j.bbrc.2010.04.017. View

Gonzalez-Gross M, Sola R, Albers U, Barrios L, Alder M, Castillo M . B-vitamins and homocysteine in Spanish institutionalized elderly. Int J Vitam Nutr Res. 2007; 77(1):22-33. DOI: 10.1024/0300-9831.77.1.22. View

Chen X, Song Rong S, Xu Q, Tang F, Liu Y, Gu H . Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis. PLoS One. 2014; 9(9):e108196. PMC: 4169602. DOI: 10.1371/journal.pone.0108196. View

Lai S, Liao K, Lin C, Lin C, Lin C . Longitudinal data of multimorbidity and polypharmacy in older adults in Taiwan from 2000 to 2013. Biomedicine (Taipei). 2021; 10(2):1-4. PMC: 7608846. DOI: 10.37796/2211-8039.1013. View

Chapman L, Darling A, Brown J . Association between metformin and vitamin B deficiency in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2016; 42(5):316-327. DOI: 10.1016/j.diabet.2016.03.008. View

Ting R, Szeto C, Chan M, Ma K, Chow K . Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med. 2006; 166(18):1975-9. DOI: 10.1001/archinte.166.18.1975. View

Grimmsmann T, Himmel W . Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?. Eur J Clin Pharmacol. 2011; 67(8):847-54. PMC: 3134712. DOI: 10.1007/s00228-011-1014-7. View

Huang K, Chang Y, Gau S, Tsai T, Lee C . Dose-Response Association of Metformin with Parkinson's Disease Odds in Type 2 Diabetes Mellitus. Pharmaceutics. 2022; 14(5). PMC: 9147745. DOI: 10.3390/pharmaceutics14050946. View

Al-Hamdi A, Al-Gahhafi M, Al-Roshdi S, Jaju S, Al-Mamari A, Al Mahrezi A . Vitamin B12 Deficiency in Diabetic Patients on Metformin Therapy: A cross-sectional study from Oman. Sultan Qaboos Univ Med J. 2020; 20(1):e90-e94. PMC: 7065694. DOI: 10.18295/squmj.2020.20.01.013. View

10.

Ibrahim A, Mander S, Hussein K, Elsherbiny N, Smith S, Al-Shabrawey M . Hyperhomocysteinemia disrupts retinal pigment epithelial structure and function with features of age-related macular degeneration. Oncotarget. 2016; 7(8):8532-45. PMC: 4890985. DOI: 10.18632/oncotarget.7384. View

11.

Vassilev Z, Ruigomez A, Soriano-Gabarro M, Garcia Rodriguez L . Diabetes, cardiovascular morbidity, and risk of age-related macular degeneration in a primary care population. Invest Ophthalmol Vis Sci. 2015; 56(3):1585-92. DOI: 10.1167/iovs.14-16271. View

12.

Brown E, Ball J, Chen Z, Khurshid G, Prosperi M, Ash J . The Common Antidiabetic Drug Metformin Reduces Odds of Developing Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2019; 60(5):1470-1477. PMC: 6736343. DOI: 10.1167/iovs.18-26422. View

13.

Hsieh C, Su C, Shao S, Sung S, Lin S, Kao Yang Y . Taiwan's National Health Insurance Research Database: past and future. Clin Epidemiol. 2019; 11:349-358. PMC: 6509937. DOI: 10.2147/CLEP.S196293. View

14.

Clemons T, Rankin M, McBee W . Cognitive impairment in the Age-Related Eye Disease Study: AREDS report no. 16. Arch Ophthalmol. 2006; 124(4):537-43. PMC: 1472655. DOI: 10.1001/archopht.124.4.537. View

15.

Nitsch D, Douglas I, Smeeth L, Fletcher A . Age-related macular degeneration and complement activation-related diseases: a population-based case-control study. Ophthalmology. 2008; 115(11):1904-10. DOI: 10.1016/j.ophtha.2008.06.035. View

16.

Huang K, Lee C, Cheng Y, Gau S, Tsai T, Chung N . Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study. Front Endocrinol (Lausanne). 2022; 13:1027484. PMC: 9748475. DOI: 10.3389/fendo.2022.1027484. View

17.

Chen Y, Shen Y, Lai Y, Wang C, Lin K, Feng S . Association between Metformin and a Lower Risk of Age-Related Macular Degeneration in Patients with Type 2 Diabetes. J Ophthalmol. 2019; 2019:1649156. PMC: 6875398. DOI: 10.1155/2019/1649156. View

18.

Romdhoniyyah D, Harding S, Cheyne C, Beare N . Metformin, A Potential Role in Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. Ophthalmol Ther. 2021; 10(2):245-260. PMC: 8079568. DOI: 10.1007/s40123-021-00344-3. View

19.

Topouzis F, Anastasopoulos E, Augood C, Bentham G, Chakravarthy U, de Jong P . Association of diabetes with age-related macular degeneration in the EUREYE study. Br J Ophthalmol. 2009; 93(8):1037-41. DOI: 10.1136/bjo.2008.146316. View

20.

Xu L, Kong L, Wang J, Ash J . Stimulation of AMPK prevents degeneration of photoreceptors and the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2018; 115(41):10475-10480. PMC: 6187182. DOI: 10.1073/pnas.1802724115. View